How to Gather Medical Records for a Reglan Tardive Dyskinesia Case in Ohio

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure Concerns

If you or a loved one developed tardive dyskinesia after taking Reglan, you may be wondering what medical records are needed to support a potential claim. The medical community has long recognized the importance of thorough documentation in assessing medication-related adverse events. This page outlines the specific medical records Ohio residents should gather to build a complete picture of Reglan use and the onset of tardive dyskinesia symptoms.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux that does not respond to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the manufacturer advises using the drug for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration with metoclopramide products, including Reglan tablets, should not exceed 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Clinical Presentation and Risk Factors for Tardive Dyskinesia

Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD occur, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome should be avoided, and Reglan should not be used in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning clearly states the risk, the importance of short-term use, and the need for immediate discontinuation if TD symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, patients who were prescribed Reglan for longer than the recommended 12-week period, or who were not adequately monitored, may have been exposed to an increased risk of developing TD. The timeline between exposure and documented harm is critical: TD can develop after months or years of metoclopramide use, and the risk is cumulative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD manifests, it may be irreversible, and the drug's ability to mask symptoms can delay diagnosis and treatment.

Statute of Limitations for Reglan Claims in Ohio

For affected patients in Ohio, settlement-related considerations involve the statute of limitations for filing a claim. The statute of limitations is a legal time limit within which a lawsuit must be filed. In Ohio, the statute of limitations for personal injury claims, including those related to drug-induced harm such as TD, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This means that patients who developed TD after taking Reglan must be aware of the time frame for legal action. The timeline between exposure and documented harm is crucial because TD may not be diagnosed until years after Reglan use began or ended. Patients should seek legal advice promptly to determine whether their claim falls within the applicable statute of limitations. In summary, Reglan carries a well-documented risk of causing tardive dyskinesia, with the risk increasing with longer use and higher cumulative doses. The drug's labeling emphasizes short-term use and monitoring, but patients who were prescribed Reglan for extended periods or without adequate warnings may have suffered harm. In Ohio, the statute of limitations for such claims is typically two years from discovery of the injury, making timely legal consultation essential for affected individuals.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Ohio?

In Ohio, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. It is important to consult with an attorney promptly to ensure your claim is filed within this time frame.

Can tardive dyskinesia from Reglan be reversed?

Tardive dyskinesia is often irreversible, even after discontinuing Reglan. The drug may also mask symptoms, delaying diagnosis. Early detection and discontinuation of Reglan are critical to potentially reducing the severity of the condition.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.